- 中文名稱
Anti-Human ULBP-2
- 英文名字
- Anti-Human ULBP-2
- 供應商
- ReliaTech
- 產品貨號
- 101-M694
- 產品報價
- ¥詢價/100ug

- 產品說明書
- 點擊查看
- 購買方式
- 90%產品中國有現貨庫存。銀行轉賬、電匯、支票、現金,在線支付寶及網銀支付,或直接與我們電話聯系400-6800-868
- 產品新聞

- 背景資料
- ULBPs activate multiple signaling pathways in primary NK cells, resulting in the production of cytokines and chemokines. Binding of ULBPs ligands to NKG2D induces calcium mobilization and activation of the JAK2, STAT5, ERK and PI3K kinase/Akt signal transduction pathway. The name ULBP derives from the original identification of three proteins, ULBP-1, -2, and -3, as ligands for the human cytomegalovirus glycoprotein UL16; they were designated UL16 binding proteins (ULBP). The genes for ULBPs reside in a cluster of ten related genes, six of which encode potentially functional glycoproteins. ULBP-2 has also been described under the names RaeT1H (retinoic acid early transcript), NKG2DL2, and ALCAN-alpha. ULBP-5 is also known as RaeT1G and ULBP-6 is also known as RaeT1L. These proteins are distantly related to MHC class I proteins, but they possess only the alpha 1 and alpha 2 Ig-like domains, and they have no capacity to bind peptide or interact with beta 2-Microglobulin. Some family members, including ULBP-2, are anchored to the membrane via a GPI-linkage, whereas others have transmembrane domains. Engagement of NKG2D results in the activation of cytolytic activity and/or cytokine production by these effector cells. The ULBPs are expressed on some tumor cells and have been implicated in tumor surveillance. Over aa 26-217, ULBP-2 shares 92% and 95% aa sequence identity with the human ULBP-5 and ULBP-6, respectively.
- 應用類型
- FC, N
- 免疫原
- 該Anti-Human ULBP-2的詳細信息查看ReliaTech提供的產品說明書。
- 來源宿主
- 該Anti-Human ULBP-2的詳細信息查看ReliaTech提供的產品說明書。
- 反應性
- 該Anti-Human ULBP-2的詳細信息查看ReliaTech提供的產品說明書。
- 保存建議
- 該Anti-Human ULBP-2的詳細信息查看ReliaTech提供的產品說明書。溶解建議:Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.
- 其他
- ReliaTech全稱為受體配體技術有限公司 (Receptor Ligand Technologies GmbH),1999年成立,總部位于德國不倫瑞克,是一家后基因組生物技術公司。ReliaTech主要專注于受體和配體的發現與研究。此外,ReliaTech也開發應用于血管與淋巴管生成研究的相關高品質試劑。目前ReliaTech提供近2800款產品,產品線主要包括重組蛋白(細胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。

- 注意
-
該頁面的中文產品信息的翻譯,僅供參考。準確的產品信息請以廠家的英文說明書為準。下單前,請瀏覽說明書確認。
-